Fibrosarcoma

Taken together, endothelial TFEB protects against EC damage and cardiac dysfunction, constituting a potential target for treating cardiotoxicity induced by DOX. Our study provides new mechanistic insights into cardiotoxicity associated with chemotherapy.

Through integrated histopathological, immunohistochemical, and molecular analyses, we characterize the diagnostic nuances, biological behavior, and potential drivers of progression in this entity. Our findings expand the morphological and clinical spectrum of LMNA::NTRK1-rearranged tumors and highlight the need for close follow-up and consideration of adjuvant targeted therapy in high-risk cases.

Initial chemotherapy with the VAC regimen (vincristine, actinomycin D, and cyclophosphamide) was administered, but the response was poor. To our knowledge, this is the first reported case of infantile fibrosarcoma with RBPMS-NTRK3 fusion in China. Treatment with larotrectinib resulted in marked tumor shrinkage.

The lung metastases appeared as multiple nodules with irregular or smooth margins in both lungs and showed variable FDG uptake, ranging from low-grade to high-grade activity, which may reflect different biologic behavior of these tumors. The lung tumors disappeared or decreased significantly in size after tropomyosin receptor kinase inhibitor therapy.

In vivo experiments confirmed the therapeutic efficacy of UA eye drops via the EGFR/RAS/RAF/MAP2K1/MAPK1 pathway. Collectively, these findings underscore the potential of UA eye drops as a promising therapeutic approach for managing ocular surface disorders in DE.

These data identify tolerated dose levels for a novel, intravenously delivered STING agonist compound that results in on-target effects in systemic and intratumoral immune responses in dogs with solid tumors.

These cases expand the landscape of FOXO1-rearranged neoplasms and describe a potential new uterine mesenchymal entity. Further study of additional cases is needed to establish whether these rearrangements truly represent an initiating event for a distinct subset of uterine sarcomas, or whether FOXO1 rearrangements simply represent an additional noninitiating/nondriver event within other established tumor types.

Inhibitors of CXCR3 or RAF reversed these effects, confirming that CXCL10 promoted M2 polarization via the CXCR3/RAF/ERK pathway. Overall, the CXCL10/CXCR3 axis played a key role in CRC progression by inducing M2 polarization of macrophages via the RAF/ERK pathway, suggesting that CXCL10/CXCR3 axis may be a potential therapeutic target for CRC immunotherapy.

This fusion drives tumorigenesis and forms the basis for imatinib treatment, which acts by blocking platelet-derived growth factor receptor-beta kinase activity...In this editorial commentary, we briefly highlight the ever-growing genomic landscape of DFSP, report rare fusions and their biological implications, and examine the role of expanded molecular diagnostics in refining diagnosis, guiding therapy, and informing prognosis. Incorporating comprehensive fusion analysis into routine workup may be critical for accurate classification, especially in unusual presentations where reliance on morphology alone risks misdiagnosis.

In children with NTRK fusion-positive sarcomas, upfront TRK inhibition yielded faster, deeper responses and eliminated mutilating surgery in our cohort. These data support TRK inhibitors as preferred neoadjuvant options, particularly to facilitate non-morbid resections and to avoid functional disability.

Its presence in a substantial portion of AFO/AFD/DO, together with their larger size compared to OD, could support a neoplastic nature in at least a subset of these lesions, though a hamartomatous DO may exist. Further investigation and clinical correlation remain essential to distinguish these entities.

P2, N=33, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Jul 2027